Anaveon transforms cytokines into treatments for cancer immunotherapy. The company is developing ANV419, an IL-2/anti-IL-2 antibody fusion protein with CD8+ T and natural killer cell-stimulating capacity.
investor of
competitor of
Metrics
marketPRIVATE
msh_idCOM:ANAVEON
localech
websitehttps://anaveon.com
source_refec1fc1d9-8c14-4ab5-af56-432bcac42080
products_or_servicesDevelopment of cancer immunotherapy treatments, specifically ANV419, an IL-2/anti-IL-2 antibody fusion protein
Switzerland